The accumulation of senescent cells is a major cause of age-related inflammation and predisposes to a variety of age-related diseases1. However, little is known about the molecular basis underlying this accumulation and its potential as a target to ameliorate the ageing process. Here we show that...
原文出处:U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma 版权声明 本网站所有注明“来源:生物谷”或“来源:bioon...
PD-L1 is often overexpressed in different tumors, and its interaction with PD-1 on T cells enables cancer cells to evade T-cell-mediated immune responses11. Thus, blocking the PD-1/PD-L1 interaction can restore T-cell activation and antitumor responses12,13,14. The success of antibody-based...
Therefore, blocking the interactions between PD-1 and its ligands can partly reduce the effect of tumor immune escape and rescue the cytotoxic cell-induced immune response [21]. PD-1 is expressed on a large proportion of tumor-infiltrating lymphocytes (TILs) from many different cancer types. PD...
blocking antibody in this combination is not recommended outside of controlled clinical trials. Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman. If used during pregnancy, or if the patient becomes pregnant during treatment, app...
For most cancer patients, PD-1/PD-L1 pathway is not the sole speed-limiting factor of antitumor immunity, and it is insufficient to motivate effective antitumor immune response by blocking PD-1/PD-L1 axis. It has been validated that some combination therapies, including α-PD-1/PD-L1 plus...
4. Heinzerling, L., et al., Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer, 2016. 4: p. 50. 5. Larsen, M., V. Appay, and D. Sauce, [Influence of PD-1 on the immunological synapse: a facet of immune regulation ?]. Med Sci (Paris), 2013...
Cancer immunotherapy has greatly advanced in recent years,and PD-1/PD-L1 blocking therapy has become a major pillar of immunotherapy.Successful clinical tr... Long,Jia,Qi,... - 《Cancer Biology & Medicine》 被引量: 2发表: 2018年 PD-1/PD-L1 pathway blockade works as an effective and pra...
Pembrolizumab is a programmed death receptor-1 (PD-1) blocking monoclonal antibody. It can block the immunosuppression mediated by the PD-1 pathway through blocking the interactions between PD-1 and PD-L1/PD-L2, and play a role in tumor immune function. It was the first PD-1 inhibitor appr...
Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells. Clin Cancer Res. 2023;29:621–34. Article PubMed Central Google Scholar Li H, Li X, Liu S, Guo L, Zhang B, Zhang J, et al. Programmed cell death-1 (PD-1) ...